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Polyunsaturated fatty acid (PUFA) status has been associated with neuropsychiatric
disorders, including depression and risk of suicide. Long-chain PUFAs (LC-PUFAs)
are obtained in the diet or produced by sequential desaturation and elongation of
shorter-chain precursor fatty acids linoleic acid (LA, 18:2n-6) and α-linolenic acid
(ALA, 18:3n-3). We compared DNA methylation patterns in genes involved in LC-
PUFA biosynthesis in major depressive disorder (MDD) with (n=22) and without
(n=39) history of suicide attempt, and age- and sex-matched healthy volunteers
(n=59). Plasma levels of selected PUFAs along the LC-PUFA biosynthesis pathway
were determined by transesterification and gas chromatography. CpG methylation
levels for the main human LC-PUFA biosynthetic genes, fatty acid desaturases 1
(Fads1) and 2 (Fads2), and elongation of very long-chain fatty acids protein 5 (Elovl5),
were assayed by bisulfite pyrosequencing. Associations between PUFA levels and
diagnosis or suicide attempt status did not survive correction for multiple testing.
However, MDD diagnosis and suicide attempts were significantly associated with
DNA methylation in Elovl5 gene regulatory regions. Also the relative roles of PUFA
levels and DNA methylation with respect to diagnostic and suicide attempt status
were determined by least absolute shrinkage and selection operator logistic regres-
sion analyses. We found that PUFA associations with suicide attempt status were
explained by effects of Elovl5 DNA methylation within the regulatory regions. The
observed link between plasma PUFA levels, DNA methylation, and suicide risk may
have implications for modulation of disease-associated epigenetic marks by nutritional
intervention.
Keywords: DNA methylation, epigenetics, suicide, major depressive disorder, polyunsaturated omega-3/omega-6
fatty acids, Fads1 fatty acid desaturase, elongation of very long-chain fatty acids protein 5
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Introduction
Imbalances in polyunsaturated fatty acids (PUFAs) may con-
tribute to psychiatric illness, including mood disorders and sui-
cidal behavior (1). PUFAs are not endogenously produced in
humans and thus must be derived from diet. Flax seeds, eggs
from n-3 (omega-3) PUFA-fed chickens, and oily fish – including
salmon, herring, and sardines, tend to contain the highest levels
of n-3 PUFAs compared to other sources. Although intake is
undoubtedly a major determinant of PUFA effects since long-
chain (LC)-PUFAs cannot be manufactured de novo in mammals,
additional physiological factors affecting PUFA bioavailability
may also mediate the clinical effects of low n-3 PUFA levels. Rele-
vant here is the sequential desaturation and elongation pathway
that produces LC-PUFAs from shorter-chain precursor PUFAs
linoleic acid (LA, 18:2n-6) and α-linolenic acid (ALA, 18:3n-3)
(Figure 1). The principal enzymatic reactions involved are ∆6-
desaturation (2) and ∆8-desaturation (3) catalyzed by the fatty
acid desaturase 2 (Fads2) gene product;∆5-desaturation catalyzed
by the fatty acid desaturase 1 (Fads1) gene product (4); and elon-
gase reactions catalyzed by the elongation of very long-chain fatty
acids proteins (Elovl5 and Elovl2) gene products (5) (see Figure 1).
n-3 PUFAs are critical to brain development, mental and neu-
rological health, and cognitive functioning. In brain, docosahex-
aenoic acid (DHA, 22:6n-3), the end product of the n-3 PUFA
biosynthetic pathway, tends to accrue in growth cones, synap-
tosomes, astrocytes, myelin, as well as microsomal and mito-
chondrial membranes (8). n-3 PUFAs are also involved in synap-
togenesis and neurite outgrowth (9) as well as neurotransmit-
ter signaling. Specifically, proper dopaminergic and serotonergic
functioning – pathways implicated inmood disorders and suicidal
behavior – rely on n-3 fatty acids (10). The potential importance of
omega-3 PUFAs to major depression has been demonstrated in a
number of observational studies (11) and randomized controlled
trials, with n-3 PUFAs showing effect sizes comparable to antide-
pressants (12, 13), and equivalent therapeutic effects to fluoxetine
in a comparative study (14).
A number of studies have suggested a role for low n-3 PUFA
intake in suicidal behavior. Suicide risk (15) and, in women,
suicidal ideation (16) may be reduced in those who consume
larger quantities of fish. n-3 PUFA levels are very low in sui-
cide completers (17) and lower in attempters retrospectively (18)
compared to depressed non-attempters, and we (19) found that
low levels of DHA in major depressive disorder (MDD) patients
predicted suicide attempt within 2 years. No differences in brain
n-3 PUFA levels were detected in initial postmortem studies
of adult and adolescent suicides compared with non-psychiatric
controls (20–22), but differences in DHA levels emerged when
depressed suicide completers were compared with controls with-
out the confound of cardiovascular disease, also associated with
low DHA (23).
Although not in the context of suicidal or related psychopathol-
ogy, the role of diet in inducing chromatin and gene expres-
sion changes has been investigated by studying PUFA intake and
expression of related biosynthetic enzymes. Studies in animals
(7, 24–26) found that experimental changes in fat intake induce
significant alterations in expression and activity of enzymes
involved in PUFA biosynthesis, which can be mediated by DNA
methylation status. For example, in a mouse model, methyla-
tion of Fads2 promoter and intron 1 is increased in mothers
and offspring when the diet is enriched in the n-3 PUFA ALA
during pregnancy (26). DNA methylation, which occurs on the
carbon-5 position of cytosines predominantly within CpG dinu-
cleotides, is typically associated with repression of gene expres-
sion. For instance, in rats, high maternal fat intake during preg-
nancy and lactation increases Fads2 promoter methylation status
and decreases Fads2 expression (25), as well as altering PUFA
concentrations in liver phosphatidylcholine (PC) (25), effects that
are reversed by switching to a soybean oil diet (25). In humans
too, supplementation with n-3 PUFA induces changes in Fads2
and Elovl5methylation status inverse to transcription rates (27).
In this study, we hypothesized that DNA methylation pat-
terns in genes involved in PUFA biosynthesis may correlate with
n-3 PUFA levels differentially in MDD compared with con-
trols, and within MDD, in suicide attempters compared with
non-attempters. We assayed CpG methylation levels in Fads1,
Fads2, and Elovl5 genes, examining methylation patterns within
cytosine-rich CpG islands associated with Fads1 and Fads2, as
well as upstream and downstream regions proximal to the islands
(denoted as CpG island shores). These shores tend to show tissue-
and species-specific patterns of DNA methylation (28, 29). In
contrast to hypomethylated CpG islands that tend to be highly
conserved, the shore regions are ideally suited for targeted assess-
ment of DNAmethylation variation in clinical samples as used in
the present study.
Materials and Methods
Samples
Written informed consent was obtained from adult participants
(n= 120) in mood disorder studies approved by the New York
State Psychiatric Institute’s Institutional Review Board. Partici-
pants includedMDD patients (n= 61) and healthy control volun-
teers (n= 59), diagnosed using the Structured Clinical Interview
for DSM-IV-TR Axis I Disorders (SCID-I) (30) and the SCID-I
non-patient version (30), respectively (Table 1). At study entry,
MDD patients had a depression severity score of at least 16 on
the 17-item Hamilton Depression Rating Scale (31). We obtained
a detailed history of each suicide attempt, defined as a self-
destructive act with some intent to die. Determination of suicide
attempts was made by consensus of expert research clinicians
(inter-rater reliability coefficient: 0.97) using the Columbia Sui-
cide History Form (32) according to criteria from the Columbia-
Classification Algorithm for Suicide Attempts, based on nomen-
clature proposed by O’Carroll et al. (33). Participants were
excluded if they had a history of neurological illness, active medi-
cal disease, or substance dependence. Depressed participants were
required to be of antidepressant medications for at least 14 days
(6weeks for fluoxetine) prior to assessments to limit the potential
confounding affect of these medications on PUFAs.
Determination of PUFA Levels
Plasma PUFAs were purified as previously described (34). Briefly,
direct transesterification (35) produced fatty acid methyl esters
(FAMEs), which were extracted with hexane and subjected to
gas chromatography according to a standardized procedure with
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FIGURE 1 | LC-PUFA biosynthesis pathway {adapted from Refs. (6, 7)}. PUFA species and biosynthetic genes included in these analyses are indicated in bold.
TABLE 1 | Demographics of sample participants by group.
Controls
(n= 59)
MDD total
(n= 61)
t/X2 p MDD non-attempters
(n= 39)
MDD suicide
attempters (n= 22)
t/X2 p
Age Mean (SD) 36.9 (13.33) 35.1 (11.84) 0.8 0.452 36.6 (11.73) 32.6 (11.87) 1.3 0.211
Male 25 (42%) 29 (48%) 0.3 0.569 19 (49%) 10 (45%) 0.1 0.806
Ethnicity 2.8 0.094 0.3 0.605
Hispanic 9 (15%) 17 (28%) 10 (26%) 7 (32%)
Non-Hispanic 50 (85%) 44 (72%) 29 (74%) 15 (68%)
Race 5.6 0.038 0.1 0.932
Caucasian 28 (47%) 42 (69%) 27 (69%) 15 (68%)
Non-Caucasian 31 (53%) 19 (31%) 12 (31%) 7 (32%)
Bold text indicates significance.
highly consistent retention times. A representative sample of
PUFA species along the biosynthetic pathway (see Figure 1) was
chosen for quantification, and product/precursor ratios between
consecutive steps along the pathway were calculated as surrogate
indices of desaturase and elongase activity.
DNA Methylation Assay via Bisulfite Sequencing
We targeted regions proximal to the transcription start site (TSS)
of Fads1, Fads2, and Elovl5 genes for methylation pyrosequenc-
ing (Table S1 in Supplementary Material). DNA was isolated
from buffy coat via column purification using the QIAamp DNA
Blood Mini Kit (Qiagen, Valencia, CA, USA), following the
manufacturer’s protocol. DNA quantity was measured using a
Qubit 2.0 Fluorometer and the Qubit dsDNA BR Kit (Life Tech-
nologies). DNA was then bisulfite treated by the EpiTect Bisulfite
Kit (Qiagen, Valencia, CA, USA) using the manufacturer’s proto-
col. Methylation primers for the regions of interest were designed
using PyromarkAssayDesign Software (version 2.01.15) included
with the Pyromark Q96 MD (Qiagen, Valencia, CA, USA), and
PCR was performed on 10 µmol of both the forward and reverse
primers using theTaqDNAPolymerase kit (Qiagen, Valencia, CA,
USA). End-point PCR was performed for 45 cycles in a Bio-Rad
MyCycler (Hercules, CA, USA) to ensure that all the primers were
consumed, with the following cycling parameters used: 15min at
95°C, 58°C for 30 s, 50°C for 30 s, and 95°C for 30 s. The primers
were synthesized by Integrated DNATechnologies (Coralville, IA,
USA), and the reverse primer from each set was biotinylated at
Frontiers in Neurology | www.frontiersin.org April 2015 | Volume 6 | Article 923
Haghighi et al. DNA methylation, fatty acids, and suicide
the 50 end. Primers used and the regions targeted are described in
Table S1 in Supplementary Material.
Primer specificity for detecting methylated, bisulfite converted
DNA was evaluated using 0–100% methylated, bisulfite con-
verted DNA in 25% steps using the reagents provided by the
EpiTect Control DNA kit (Qiagen, Valencia, CA, USA), with all
primers used having expected linear standard curves. Methy-
lation pyrosequencing was performed using a Pyromark Q96
MD, using the Pyromark Gold Q96 CDT Reagents following
manufacturer’s instructions (both Qiagen, Valencia, CA, USA).
Five microliters of amplified DNA product was mixed with 2 µl
Streptavidin Sepharose beads (GE Healthcare, Rahway, NJ, USA),
40 µl binding buffer (Qiagen, Valencia, CA, USA), and 33 µl of
nuclease free water (Life Technologies, Grand Island, NY, USA),
followed by shaking on a P2 Orbit Digital Shaker (Labnet, Edison,
NJ, USA) at 1400 rpm for 10min. The immobilized biotinylated
PCR product–Streptavidin Sepharose bead complex was captured
using theVacuumPrepWorkstation (Qiagen,Valencia, CA,USA),
and single strand purification was achieved by washing the vac-
uum prep tool sequentially with 75% ethanol, 0.2M NaOH, and
washing buffer (Qiagen, Valencia, CA, USA) for 30 s each. The
unbiotinylated strand was dissociated and discarded, and the
biotinylated strands were released to a 96-well microtiter plate,
which contained 10.8 µl of annealing buffer (Qiagen, Valencia,
CA, USA) and 1.2 µl complementary sequencing primer in each
well. The plate was incubated at 80°C for 2min, followed by slow
cooling to room temperature. The processed mixture was loaded
onto the PyroMark MD system equipped with PyroMark MD
software for pyrosequencing, and the resulting pyrograms and
associated sequences were generated and analyzed automatically
using the PyroMark MD software.
Statistical analysis
Methylation levels were averaged by region for each gene (Fads1,
Fads2, and Elovl5), using 5% trimming to avoid outlier sites
within subject that could skew the average value. To mitigate
the presence of outliers and skewed distribution, log-transformed
PUFA andmethylation values were used in all group comparisons.
Separate ANCOVA models were employed to test for diagnostic
group differences in PUFA and methylation levels, adjusted for
age and sex. Two comparisons were run: (1) all MDD patients
vs. healthy controls and (2) MDD attempters vs. MDD non-
attempters. Significance levels were adjusted for multiple testing
using the Benjamin–Hochberg linear step-down method (36), to
preserve an experiment-wise false discovery rate of 5%. Significant
models for MDD were adjusted for ethnicity and race. Next, all
biological measures (and age and sex) were tested simultaneously
as predictors of diagnosis and attempt. There were too many pre-
dictors compared to the group sample size, so, being cognizant of
the shortcoming of stepwise variable selectionmethods, we used a
feature selection technique that employs cross-validation to select
themost important features.We performedmodel selection using
the least absolute shrinkage and selection operator (LASSO) (37,
38) function cv.glmnet in the statistical language R, starting from
the full set of PUFA and methylation variables (including age,
sex, ethnicity, and race), with no pre-screening, and using cross-
validation to select the optimal model. Since the LASSO logistic
model does not currently provide a way to calculate significance
levels, the variables in the final model were used as predictors
in a logistic regression and these results are also provided for
comparison.
Results
For this study, we enrolled healthy volunteers/controls (n= 59)
and patients with DSM-IV diagnosis of MDD (n= 61) with
(n= 22) and without (n= 39) a history of suicide attempt,
18–73 years of age (mean age: 36 13 years, Table 1). The pro-
portion ofCaucasian subjects was significantly higher in theMDD
group than among healthy volunteers; the groups were otherwise
balanced.
Fatty Acid Differences Across Diagnostic Groups
We found pointwise significant differences between MDD
and healthy volunteer subjects, with respect to PUFAs (Table
S2 in Supplementary Material); however, none were signifi-
cant after multiple testing correction (k= 25 tests, using Ben-
jamini–Hochberg adjustment). For 18:3n-3 (ALA), 20:5n-3
(EPA), and 20:2n-6, the MDD group had lower levels on the
0.05 level as compared to controls. Numeric differences were
similarly seen in ratios of certain longer- to shorter-chain PUFAs,
providing indirect indices of activity of enzymes in the LC-
PUFA biosynthetic pathway. The ratio 22:5n-3/20:5n-3, reflecting
elongase (Elovl5) activity, was higher in MDD, as was the ratio
20:3n-6/20:2n-6, which reflects ∆8-desaturase activity (Fads2),
whereas the ratio 22:6n-3/22:5n-3, which reflects ∆-6 desaturase
activity but also includes elongase (Elovl2) and β-oxidation steps,
was lower (see Figure 1, Table S2 in Supplementary Material).
Within the MDD group comparing suicide attempters and non-
attempters, differences in the 22:4n-6 and its ratio with 20:4n-6,
reflecting elongase (Elovl5) activity, were detected but were no
longer significant after adjustment for multiple testing. Interest-
ingly, these were both higher in suicide attempters, and trend
associations were seen in attempters with higher 22:5n-3 (DPA)
levels and lower ratios of 20:3n-6/18:3n-6, also reflecting elongase
(Elovl5) activity. Our study was powered to detect relatively large
(Cohen’s d> 0.7) effect sizes for a diagnosis of MDD, and very
large (d> 1) effect sizes for suicide attempt after adjustment for
multiple testing; thus, larger or more focused studies are needed
for confirmatory analysis of the risk associated with some of these
biological measures. All comparisons were adjusted for age and
sex; adjusting for ethnicity and race did not alter the significance
levels.
DNA Methylation Differences Across Diagnostic
Groups
Using methylation pyrosequencing, we assayed DNAmethylation
patterns across regulatory regions of Fads1, Fads2, and Elovl5
genes (seven separate regions, see Figure S1 in Supplementary
Material). Across the diagnostic groups, the MDD patients exhib-
ited a trend toward lower CpG methylation within the Fads2
upstream but higher methylation at the Elovl5 upstream proximal
regions from the TSS as compared to controls (Table 2 and Figure
S1 in Supplementary Material). Within the MDD group, suicide
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TABLE 2 |Methylation levels (log-transformed) by group.
Methylation
sites
Controls
(n= 59)
MDD
(n= 61)
Comparison
(adj. for age and sex)
MDD
non-attempters
(n= 39)
MDD suicide
attempters
(n= 22)
Comparison
(adj. for age and sex)
Mean SD Mean SD t-score p Adj. p Mean SD Mean SD t-score p Adj. p
Fads1U 2.79 0.39 2.75 0.31  0.50 0.620 0.620 2.76 0.37 2.71 0.16  0.85 0.396 0.554
Fads1CpG 1.27 0.28 1.23 0.29  0.62 0.535 0.620 1.24 0.29 1.20 0.28  0.64 0.524 0.611
Fads1D 1.21 0.41 0.96 0.89  2.01 0.046 0.107 1.02 0.73 0.84 1.14  0.94 0.349 0.554
Fads2U 2.97 0.42 2.79 0.39  2.54 0.012 0.042 2.79 0.44 2.80 0.27  0.35 0.726 0.726
Fads2D 4.21 0.19 4.27 0.16 1.56 0.121 0.212 4.24 0.18 4.31 0.08 0.97 0.335 0.554
ElovlU 2.26 0.57 2.53 0.58 2.54 0.012 0.042 2.36 0.48 2.85 0.62 3.29 0.002 0.007
ElovlD 1.88 0.26 1.84 0.25  0.64 0.526 0.620 1.91 0.26 1.70 0.19  3.74 <0.001 0.003
“U” and “D” refer to upstream and downstream sites, respectively. MDD, major depressive disorder. Significant p-values after adjustment for multiple testing at the FDR=0.05 level
are shown in bold.
attempters showed significantly lower CpG methylation levels
within the downstream Elovl5 TSS region (p= 0.0028 adjusted)
but higher methylation in the upstream Elovl5 region compared
toMDDnon-attempters (p= 0.0036 adjusted;Table 2). Adjusting
for race and ethnicity did not alter the findings.
Contribution of Fatty Acid and DNA Methylation
Signatures to Diagnostic Outcome
Spearman correlation coefficients computed between PUFA and
DNA methylation measures indicate that there are some strong
associations between measures in the two groups. 25 out of the
175 pairs (14%) were significantly correlated after adjustment
for multiple testing at the FDR= 5% level (data not shown). In
an effort to understand the relative contributions of PUFA and
methylation patterns to disease risk with respect to MDD and to
suicidal behavior, we performed model selection using LASSO
logistic regression, starting with the full set of PUFA andmethyla-
tion variables (including age, race, ethnicity, and sex, resulting in
36 variables), with no pre-screening, and using cross-validation to
select the optimal model. This technique shrinks the coefficients
in a (logistic) regressionmodel until some estimates become effec-
tively 0, meaning that the variable is no longer in the model. No
variables were selected for the final model with MDD diagnosis
as outcome. For suicide attempt risk within the MDD subjects,
only two biological measures remained in the final model: CpG
methylation at the Elovl5 upstream and downstream regions.
Gain and loss of methylation at the Elovl5 upstream and down-
stream regions, respectively, independently contributed to suicide
attempt risk (LASSO model with shrunk coefficients: upstream
Elovl5 methylation OR= 1.07, downstream Elovl5 methylation
OR= 0.89; logistic regression model results for the same vari-
ables: upstream: OR= 1.10, z= 2.33, p= 0.020; downstream:
OR= 0.34, z= 2.96, p= 0.003, see Table 3). Age was also
included in the final model for suicide attempt (LASSO model
OR= 0.98; logistic model OR= 0.93, z= 2.05. p= 0.040).
Discussion
We found that DNA methylation of genes involved in n-3 PUFA
biosynthesis was associated with MDD and suicide risk. PUFA
imbalances long-term could induce changes in the epigenome and
TABLE 3 | Logistic regression model with suicide attempt as outcome in
MDD patients.
Predictorsa Odds ratio 95% CI Z-statistic P-value
Lower Upper
Age 0.93 0.86 0.997  2.05 0.040
Elovl U 1.10 1.02 1.21 2.33 0.020
Elovl D 0.34 0.17 0.70  2.96 0.003
Variables for the model were selected with cross-validated LASSO logistic regression.
a“U” signifies upstream, “D,” downstream regions.
the methylome, which our data show are associated with suicide.
There is ample precedent for PUFA effects on DNA methyla-
tion states (25, 27, 39), which have been attributed to effects of
DHA on one-carbon metabolism (40). In this schema (41), DHA-
containing phosphatidyl ethanolamine (PE) is a methyl acceptor,
converted thereby to PC for PUFA transport through the blood-
stream; when DHA is in short supply, it is hypothesized that
methyl groups then may be available for other transmethylation
of DNA or histones. Two out of seven methylation measures
but no PUFA measures (out of a total of 25) made it into the
multi-predictor model of suicide attempt risk; thus, methylation
effect sizes were greater than those of PUFAs. Studies with larger
sample sizes and/or focused on fewer comparisons may identify
significant PUFA correlates of suicide attempt risk. However, it is
also possible that the risk effects associated with PUFA levels were
explained bymethylation states, whichmay serve as stable proxies
of PUFA composition.
Among MDD patients, we found that Elovl5 methylation in
suicide attempters was higher in the upstream region and lower in
the downstream region, identifying potential epigenetic markers
of suicide risk and suggesting that methylation in these two shore
regions might have opposite functional effects. The effects of
elongase activity on the generation of LC-PUFA are complex,
due to competition between n-3 and n-6 PUFAs for the catalytic
sites, the occurrence of genetic polymorphisms such as rs2397142,
which confers low Elovl5 activity (42), and the contribution of
dietary intake.
Polyunsaturated fatty acid balance has therapeutic implications
for treating chronic psychiatric disease, including MDD, bipolar
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disorder, and suicide risk. Randomized clinical trials have
found n-3 PUFA supplements rich in eicosapentaenoic acid
(EPA, 20:5n-3) to be effective in major depression (13, 43–45),
although some concern about publication bias exists (13). It is
also noteworthy that many mood stabilizing drugs (valproate,
lithium, carbamazepine, olanzapine, and clozapine) specifically
inhibit membrane turnover and downstream signaling of n-
6 PUFAs while some (fluoxetine and imipramine) but not all
(bupropion) antidepressants tested cause increased n-6 PUFA
turnover (46).
To fit models for MDD diagnosis and suicide attempt based on
all PUFA and methylation variables would require a sample size
that is beyond the scope of the current study. Stepwise variable
selection is a possible approach; however, the resultingmodel may
be unstable and significance levels unreliable.We elected to use the
LASSO method (in a logistic regression setting) and present the
resulting parsimonious model for suicide attempt risk involving
the two Elovl5methylationmeasures and age, with the odds ratios
estimated by the shrinkage method LASSO employs. We also
present inTable 3 the logistic regressionmodel based on the same
three predictors, estimated the classical way; the LASSO estimates
are noticeably smaller, toward the neutral value (OR= 1). Since
the LASSO model was selected using cross-validation, the odds
ratios reported by it are likely to be more realistic for predicting
outcome in future subjects. No variable was selected for predict-
ing MDD, perhaps indicating that the associations between the
biological variables and MDD diagnosis were not strong enough
in the present sample after cross-validation.
This study has a number of limitations. As a cross-sectional
study, it was not possible to determine how differences in DNA
methylation and PUFA composition are associated with suicide
risk long-term. Some of the results presented did not survive cor-
rection for multiple comparisons, possibly due to limited power,
and therefore future studies should investigate DNA methylation
and PUFA changes in a larger cohort. We did not examine rela-
tionships between epigenetic changes and the presence of genetic
polymorphisms, which have been shown to impact PUFA levels
[reviewed inRef. (47)].We investigatedDNAmethylation changes
within regulatory regions of genes involved in PUFA biosynthesis,
but it is likely that imbalances in dietary PUFA levels will induce
DNAmethylationmodifications on a genome-scale not examined
in this study. The lack of RNA specimens for the samples used in
the present study did not allow for assessments of the relationship
between changes in DNA methylation and corresponding gene
expression. Still, compared to RNA, DNA methylation patterns
are highly stable long-term, potentially serving as useful markers
of dietary intake and deficiencies.
Conclusion and Future Directions
These findings are intriguing because they establish the link
between imbalances in PUFA composition and DNA methyla-
tion patterns in regulatory regions of genes directly involved in
PUFA biosynthesis using a clinical cohort well-characterized with
respect to depression and history of suicidal behavior. Investiga-
tions of epigenetics and dietary PUFAs can inform our under-
standing of gene–diet interactions and their relationship to psy-
chiatric disease susceptibility and specifically, suicide risk. Future
prospective studies of PUFA supplementation that include epi-
genetic assessments could open up a novel approach to per-
sonalized treatment of depression and suicidal behavior through
modulation of disease-associated epigenetic marks by nutritional
intervention.
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